[HTML][HTML] Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life, 2023 - mdpi.com
Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life (Basel …, 2023 - europepmc.org
Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

[HTML][HTML] Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life, 2023 - ncbi.nlm.nih.gov
Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life, 2023 - search.proquest.com
Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

[PDF][PDF] Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life, 2023 - pdfs.semanticscholar.org
Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life (Basel), 2023 - go.gale.com
Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas… - Life (Basel …, 2023 - pubmed.ncbi.nlm.nih.gov
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life (2075 …, 2023 - search.ebscohost.com
Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a …

A Xanthopoulos, N Katsiadas, N Skopeliti… - European Heart …, 2023 - academic.oup.com
Abstract Introduction Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors are a relatively
new class of antidiabetic drugs, which showed favorable effects in heart failure (HF) patients …

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

A Xanthopoulos, N Katsiadas, S Skoularigkis… - Life, 2023 - ui.adsabs.harvard.edu
Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …